Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Nonacog alfa 2000 [iU] (+ 10% overage)
Pfizer New Zealand Limited
Nonacog alfa 2000 IU (+ 10% overage)
2000 IU
Powder for injection with diluent
Active: Nonacog alfa 2000 [iU] (+ 10% overage) Excipient: Glycine Histidine Polysorbate 80 Sucrose Sodium chloride Water for injection
Combination pack, vial + pre-filled syringe diluent + infusion set, 1 dose unit
General sale
General sale
Wyeth Biopharma, Division of Wyeth Pharmaceuticals Inc., a Subsidiary of Pfizer Inc.
for the control and prevention of haemorrhagic episodes in patients with haemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings.
Package - Contents - Shelf Life: Combination pack, vial + pre-filled syringe diluent + infusion set - 1 dose units - 6 months unopened stored at or below 30°C. After which cannot be returned to refrigerated conditions. 36 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) - Syringe, Pre-filled glass, Diluent - 10 mL - 48 months from date of manufacture stored at or below 30°C - Vial, glass, Powder for reconstitution - 2000 IU - 36 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)
2006-05-16
BENEFIX ® 1 BENEFIX ® _nonacog alfa (rch) (recombinant coagulation factor IX), 250, 500, 1000, 2000, 3000 IU /vial_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some of the common questions about BeneFIX. It does not contain all of the available information. It does not take the place of talking to your doctor or hospital pharmacist. IF YOU HAVE ANY CONCERNS ABOUT USING BENEFIX, ASK YOUR DOCTOR OR HOSPITAL PHARMACIST. Your doctor and hospital pharmacist have more information. KEEP THIS LEAFLET WITH YOUR BENEFIX. You may need to read it again. WHAT BENEFIX IS BeneFIX, nonacog alfa (rch) is a coagulation factor IX product that is produced by recombinant technology. Mammalian cells, which have the DNA for human coagulation factor IX put in them, are grown in large amounts in cell culture laboratories. These cells make recombinant human factor IX, which is released into cell culture media and then very highly purified. The recombinant factor IX does not contain any human blood, preservatives, or added animal or human components. WHAT BENEFIX IS USED FOR People with haemophilia B (Christmas disease) are deficient in coagulation factor IX. BeneFIX works by replacing factor IX to enable blood to clot. BeneFIX is used for the control and treatment of bleeding and the prevention of bleeding in people with haemophilia B. BeneFIX has been approved for use in haemophilia B. Ask your doctor if you have any questions about why BeneFIX has been prescribed for you. There is no evidence that BeneFIX is addictive. BeneFIX is not expected to affect your ability to drive a car or operate machinery. BEFORE YOU USE BENEFIX _WHEN YOU MUST NOT USE IT_ DO NOT USE BENEFIX IF YOU ARE ALLERGIC TO HAMSTER PROTEINS OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. Signs of allergy include a skin rash, itching, chest tightness, wheezing, dizziness, hives, faintness, rapid heartbeat, blurred vision, shortness of breath and/or a swollen face. If any of these signs occur, stop using BeneFIX and see your Read the complete document
Version: pfdbenev11218 Supersedes: pfdbenev10117 Page 1 of 13 NEW ZEALAND DATA SHEET 1. PRODUCT NAME BeneFIX 250 IU powder and solvent for solution for injection. BeneFIX 500 IU powder and solvent for solution for injection. BeneFIX 1000 IU powder and solvent for solution for injection. BeneFIX 2000 IU powder and solvent for solution for injection. BeneFIX 3000 IU powder and solvent for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of BeneFIX 250 IU powder for injection contains nominally 250 IU* of nonacog alfa (recombinant coagulation factor IX)**. After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 50 IU nonacog alfa. Each vial of BeneFIX 500 IU powder for injection contains nominally 500 IU* of nonacog alfa (recombinant coagulation factor IX)**. After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 100 IU nonacog alfa. Each vial of BeneFIX 1000 IU powder for injection contains nominally 1000 IU* of nonacog alfa (recombinant coagulation factor IX)**. After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 200 IU nonacog alfa. Each vial of BeneFIX 2000 IU powder for injection contains nominally 2000 IU* of nonacog alfa (recombinant coagulation factor IX)**. After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 400 IU nonacog alfa. Each vial of BeneFIX 3000 IU powder for injection contains nominally 3000 IU* of nonacog alfa (recombinant coagulation factor IX)**. After reconstitution with the accompanying 5 mL (0.234%) sodium chloride solution for injection, each mL of the solution contains approximately 600 IU nonacog alfa. *The potency (in international units, IU) is determined using an _in vitro_ one-stage clotting assay agai Read the complete document